image
T2 Biosystems, Inc. TTOO
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
Watchlist
$ 0.497
-4.42 %
$ 8.69 M
Market Cap
0.02
P/E
1. INTRINSIC VALUE

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus.[ Read More ]

The intrinsic value of one TTOO stock under the base case scenario is HIDDEN Compared to the current market price of 0.497 USD, T2 Biosystems, Inc. is HIDDEN

TTOO Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart TTOO

image
FINANCIALS
7.19 M REVENUE
-67.75%
Growth Rates
1Year -67.75%
3Years -26.52%
5Years -7.29%
7Years 8.44%
10Years 39.06%
-49.7 M OPERATING INCOME
10.53%
Growth Rates
1Year 10.53%
3Years -6.29%
5Years -1.95%
7Years 0.34%
10Years -9.69%
-50.1 M NET INCOME
19.23%
Growth Rates
1Year 19.23%
3Years -2.28%
5Years 0.42%
7Years 1.28%
10Years -9.28%
-48.1 M OPERATING CASH FLOW
4.92%
Growth Rates
1Year 4.92%
3Years -3.66%
5Years -3.70%
7Years -0.51%
10Years -10.30%
-192 K INVESTING CASH FLOW
-1.99%
Growth Rates
1Year -1.99%
3Years 82.57%
5Years 20.19%
7Years 38.06%
10Years 7.81%
52.7 M FINANCING CASH FLOW
81.35%
Growth Rates
1Year 81.35%
3Years -14.94%
5Years 1.19%
7Years 0.26%
10Years 3.06%
1.98 M REVENUE
1.69%
Growth Rates
1Year -67.75%
3Years -26.52%
5Years -7.29%
7Years 8.44%
10Years 39.06%
-10.2 M OPERATING INCOME
-6.12%
Growth Rates
1Year 10.53%
3Years -6.29%
5Years -1.95%
7Years 0.34%
10Years -9.69%
-10.1 M NET INCOME
-12.88%
Growth Rates
1Year 19.23%
3Years -2.28%
5Years 0.42%
7Years 1.28%
10Years -9.28%
-6.25 M OPERATING CASH FLOW
32.34%
Growth Rates
1Year 4.92%
3Years -3.66%
5Years -3.70%
7Years -0.51%
10Years -10.30%
0 INVESTING CASH FLOW
0.00%
Growth Rates
1Year -1.99%
3Years 82.57%
5Years 20.19%
7Years 38.06%
10Years 7.81%
4.09 M FINANCING CASH FLOW
-43.82%
Growth Rates
1Year 81.35%
3Years -14.94%
5Years 1.19%
7Years 0.26%
10Years 3.06%
Balance Sheet Decomposition T2 Biosystems, Inc.
image
Current Assets 25.2 M
Cash & Short-Term Investments 15.7 M
Receivables 1.42 M
Other Current Assets 8.08 M
Non-Current Assets 9.61 M
Long-Term Investments 0
PP&E 9.05 M
Other Non-Current Assets 555 K
Current Liabilities 56.2 M
Accounts Payable 1.53 M
Short-Term Debt 44.5 M
Other Current Liabilities 10.1 M
Non-Current Liabilities 6.68 M
Long-Term Debt 6.6 M
Other Non-Current Liabilities 83 K
EFFICIENCY
Earnings Waterfall T2 Biosystems, Inc.
image
Revenue 7.19 M
Cost Of Revenue 15.4 M
Gross Profit -8.17 M
Operating Expenses 41.5 M
Operating Income -49.7 M
Other Expenses 413 K
Net Income -50.1 M
RATIOS
-113.58% GROSS MARGIN
-113.58%
Averages
1Year -113.58%
3Years -27.38%
5Years -40.13%
7Years -57.87%
10Years -1695.89%
-690.45% OPERATING MARGIN
-690.45%
Averages
1Year -690.45%
3Years -364.16%
5Years -389.03%
7Years -504.10%
10Years -3210.03%
-696.19% NET MARGIN
-696.19%
Averages
1Year -696.19%
3Years -390.32%
5Years -439.91%
7Years -574.95%
10Years -3335.61%
178.62% ROE
178.62%
Averages
1Year 178.62%
3Years 250.59%
5Years 74.69%
7Years -676.37%
10Years -502.96%
-143.91% ROA
-143.91%
Averages
1Year -143.91%
3Years -138.85%
5Years -140.06%
7Years -127.67%
10Years -104.68%
-334.12% ROIC
-334.12%
Averages
1Year -334.12%
3Years -326.51%
5Years -337.19%
7Years -273.49%
10Years -207.84%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis T2 Biosystems, Inc.
image
Net Income -50.1 M
Depreciation & Amortization 859 K
Capital Expenditures -192 K
Stock-Based Compensation 4.35 M
Change in Working Capital -4.04 M
Others -3.5 M
Free Cash Flow -48.3 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets T2 Biosystems, Inc.
image
Wall Street analysts predict an average 1-year price target for TTOO of $5 , with forecasts ranging from a low of $5 to a high of $5 .
TTOO Lowest Price Target Wall Street Target
5 USD 906.04%
TTOO Average Price Target Wall Street Target
5 USD 906.04%
TTOO Highest Price Target Wall Street Target
5 USD 906.04%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION

Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners.

image
-1.43 USD
INBS
Overvalued 196.53%

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer.

image
0.134 USD
BIAF
Overvalued 89.76%

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally.

image
845 USD
TMO
Undervalued 64.71%

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

image
58.4 USD
ILMN
Overvalued 56.74%

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions.

image
230 USD
DHR
Overvalued 0.31%

Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA.

image
208 USD
WAT
Overvalued 41.87%

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide.

image
153 USD
IDXX
Overvalued 63.61%

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide.

image
0 USD
ISPC
Overvalued 100.00%
6. Ownership
Insider Ownership T2 Biosystems, Inc.
image
Sold
0-3 MONTHS
133 USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 months ago
Sep 13, 2024
Sell 133 USD
Elsbree David B
Director
- 55
 2.42 USD
1 year ago
Feb 20, 2023
Sell 349 USD
Giffin Brett A.
Chief Commercial Officer
- 537
 0.65 USD
1 year ago
Sep 27, 2023
Sell 458 K USD
CR Group L.P.
10 percent owner
- 2391981
 0.1916 USD
1 year ago
Sep 27, 2023
Sell 311 K USD
CR Group L.P.
10 percent owner
- 1621313
 0.1916 USD
1 year ago
Sep 27, 2023
Sell 285 K USD
CR Group L.P.
10 percent owner
- 1489512
 0.1916 USD
1 year ago
Sep 27, 2023
Sell 91.7 K USD
CR Group L.P.
10 percent owner
- 478396
 0.1916 USD
1 year ago
Sep 28, 2023
Sell 305 K USD
CR Group L.P.
10 percent owner
- 1937852
 0.1575 USD
1 year ago
Sep 26, 2023
Sell 433 K USD
CR Group L.P.
10 percent owner
- 2156717
 0.2007 USD
1 year ago
Sep 26, 2023
Sell 293 K USD
CR Group L.P.
10 percent owner
- 1461849
 0.2007 USD
1 year ago
Sep 26, 2023
Sell 270 K USD
CR Group L.P.
10 percent owner
- 1343011
 0.2007 USD
1 year ago
Sep 26, 2023
Sell 86.6 K USD
CR Group L.P.
10 percent owner
- 431343
 0.2007 USD
1 year ago
Sep 25, 2023
Sell 25 K USD
CR Group L.P.
10 percent owner
- 99979
 0.25 USD
1 year ago
Sep 25, 2023
Sell 16.9 K USD
CR Group L.P.
10 percent owner
- 67767
 0.25 USD
1 year ago
Sep 25, 2023
Sell 15.6 K USD
CR Group L.P.
10 percent owner
- 62258
 0.25 USD
1 year ago
Sep 25, 2023
Sell 5 K USD
CR Group L.P.
10 percent owner
- 19996
 0.25 USD
1 year ago
Sep 22, 2023
Sell 526 K USD
CR Group L.P.
10 percent owner
- 2031313
 0.2588 USD
1 year ago
Sep 22, 2023
Sell 356 K USD
CR Group L.P.
10 percent owner
- 1376848
 0.2588 USD
1 year ago
Sep 22, 2023
Sell 327 K USD
CR Group L.P.
10 percent owner
- 1264920
 0.2588 USD
1 year ago
Sep 22, 2023
Sell 105 K USD
CR Group L.P.
10 percent owner
- 406263
 0.2588 USD
1 year ago
Sep 21, 2023
Sell 762 K USD
CR Group L.P.
10 percent owner
- 2534754
 0.3005 USD
1 year ago
Sep 21, 2023
Sell 516 K USD
CR Group L.P.
10 percent owner
- 1718087
 0.3005 USD
1 year ago
Sep 21, 2023
Sell 474 K USD
CR Group L.P.
10 percent owner
- 1578419
 0.3005 USD
1 year ago
Sep 21, 2023
Sell 152 K USD
CR Group L.P.
10 percent owner
- 506951
 0.3005 USD
1 year ago
Sep 20, 2023
Sell 963 K USD
CR Group L.P.
10 percent owner
- 3100836
 0.3106 USD
1 year ago
Sep 20, 2023
Sell 653 K USD
CR Group L.P.
10 percent owner
- 2101784
 0.3106 USD
1 year ago
Sep 20, 2023
Sell 600 K USD
CR Group L.P.
10 percent owner
- 1930923
 0.3106 USD
1 year ago
Sep 20, 2023
Sell 193 K USD
CR Group L.P.
10 percent owner
- 620167
 0.3106 USD
1 year ago
Sep 19, 2023
Sell 1.52 M USD
CR Group L.P.
10 percent owner
- 4159717
 0.366 USD
1 year ago
Sep 19, 2023
Sell 1.03 M USD
CR Group L.P.
10 percent owner
- 2819506
 0.366 USD
1 year ago
Sep 19, 2023
Sell 948 K USD
CR Group L.P.
10 percent owner
- 2590300
 0.366 USD
1 year ago
Sep 19, 2023
Sell 304 K USD
CR Group L.P.
10 percent owner
- 831943
 0.366 USD
1 year ago
Mar 28, 2023
Sell 115 USD
Gibbs Michael Terrence
General Counsel
- 239
 0.481 USD
1 year ago
Feb 22, 2023
Sell 349 USD
Giffin Brett A.
Chief Commercial Officer
- 537
 0.65 USD
1 year ago
Feb 28, 2023
Sell 677 USD
Sprague John M
Chief Financial Officer
- 1148
 0.59 USD
1 year ago
Feb 22, 2023
Sell 1 K USD
Sprague John M
Chief Financial Officer
- 1545
 0.65 USD
1 year ago
Feb 28, 2023
Sell 935 USD
Gibbs Michael Terrence
General Counsel
- 1585
 0.59 USD
1 year ago
Feb 22, 2023
Sell 1.39 K USD
Gibbs Michael Terrence
General Counsel
- 2145
 0.65 USD
1 year ago
Feb 28, 2023
Sell 1.71 K USD
Sperzel John J III
Chairman and CEO
- 2898
 0.59 USD
1 year ago
Feb 22, 2023
Sell 4.47 K USD
Sperzel John J III
Chairman and CEO
- 6875
 0.65 USD
2 years ago
Nov 10, 2022
Sell 2.32 K USD
Giffin Brett A.
Chief Commercial Officer
- 1292
 1.793 USD
2 years ago
Apr 07, 2022
Bought 15 K USD
Sperzel John J III
Chairman, CEO, and President
+ 30000
 0.5 USD
2 years ago
Apr 08, 2022
Bought 6.48 K USD
Barclay Alec
Chief Operations Officer
+ 12951.88
 0.5 USD
2 years ago
Apr 07, 2022
Bought 4.9 K USD
Gibbs Michael Terrence
General Counsel
+ 10000
 0.49 USD
2 years ago
Apr 08, 2022
Bought 4.77 K USD
Sprague John M
Chief Financial Officer
+ 10000
 0.4767 USD
2 years ago
Apr 08, 2022
Bought 5.18 K USD
Giffin Brett A.
Chief Commercial Officer
+ 10600
 0.489 USD
2 years ago
Jan 06, 2022
Sell 29.8 K USD
Ahuja Aparna
Chief Medical Officer
- 61988
 0.48 USD
4 years ago
May 06, 2020
Bought 14.5 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
+ 26200
 0.5517 USD
4 years ago
May 20, 2020
Bought 4.12 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
+ 5126
 0.803 USD
4 years ago
May 06, 2020
Sell 5.76 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 10100
 0.57 USD
4 years ago
May 19, 2020
Bought 8.6 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
+ 10328
 0.8329 USD
4 years ago
May 12, 2020
Bought 1.36 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
+ 2500
 0.546 USD
4 years ago
May 19, 2020
Sell 668 USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 800
 0.8345 USD
4 years ago
Apr 09, 2020
Bought 490 USD
GOLDMAN SACHS & CO. LLC
10 percent owner
+ 1000
 0.49 USD
4 years ago
May 06, 2020
Sell 1.14 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 2000
 0.5701 USD
4 years ago
Mar 25, 2020
Bought 557 USD
GOLDMAN SACHS & CO. LLC
10 percent owner
+ 600
 0.9279 USD
4 years ago
Mar 24, 2020
Bought 189 USD
GOLDMAN SACHS & CO. LLC
10 percent owner
+ 500
 0.378 USD
4 years ago
May 06, 2020
Sell 570 USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 1000
 0.5702 USD
4 years ago
Mar 25, 2020
Sell 557 USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 600
 0.9279 USD
4 years ago
May 19, 2020
Sell 1.7 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 2031
 0.8347 USD
4 years ago
Apr 09, 2020
Sell 490 USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 1000
 0.49 USD
4 years ago
Mar 24, 2020
Sell 189 USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 500
 0.378 USD
4 years ago
May 12, 2020
Sell 1.36 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 2500
 0.546 USD
4 years ago
May 19, 2020
Sell 166 USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 200
 0.8314 USD
4 years ago
May 06, 2020
Sell 1.38 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 2655
 0.52 USD
4 years ago
May 19, 2020
Sell 2.69 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 3235
 0.8318 USD
4 years ago
May 06, 2020
Sell 521 USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 1000
 0.521 USD
4 years ago
May 06, 2020
Sell 526 USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 1000
 0.526 USD
4 years ago
May 06, 2020
Sell 264 USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 500
 0.528 USD
4 years ago
May 06, 2020
Sell 26.5 USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 50
 0.53 USD
4 years ago
May 19, 2020
Sell 1.69 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 2031
 0.8325 USD
4 years ago
May 06, 2020
Sell 266 USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 500
 0.5318 USD
4 years ago
May 06, 2020
Sell 53.2 USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 100
 0.5325 USD
4 years ago
May 19, 2020
Sell 1.69 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 2031
 0.8326 USD
4 years ago
May 06, 2020
Sell 3.38 K USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 6256
 0.54 USD
4 years ago
May 06, 2020
Sell 55 USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 100
 0.55 USD
4 years ago
May 06, 2020
Sell 517 USD
GOLDMAN SACHS & CO. LLC
10 percent owner
- 939
 0.5503 USD
4 years ago
May 06, 2020
Bought 14.5 K USD
Jones Adrian M
Director
+ 26200
 0.5517 USD
4 years ago
May 20, 2020
Bought 4.12 K USD
Jones Adrian M
Director
+ 5126
 0.803 USD
4 years ago
May 06, 2020
Sell 5.76 K USD
Jones Adrian M
Director
- 10100
 0.57 USD
4 years ago
May 19, 2020
Bought 8.6 K USD
Jones Adrian M
Director
+ 10328
 0.8329 USD
4 years ago
May 12, 2020
Bought 1.36 K USD
Jones Adrian M
Director
+ 2500
 0.546 USD
4 years ago
May 19, 2020
Sell 668 USD
Jones Adrian M
Director
- 800
 0.8345 USD
4 years ago
Apr 09, 2020
Bought 490 USD
Jones Adrian M
Director
+ 1000
 0.49 USD
4 years ago
May 06, 2020
Sell 1.14 K USD
Jones Adrian M
Director
- 2000
 0.5701 USD
4 years ago
Mar 25, 2020
Bought 557 USD
Jones Adrian M
Director
+ 600
 0.9279 USD
4 years ago
Mar 24, 2020
Bought 189 USD
Jones Adrian M
Director
+ 500
 0.378 USD
4 years ago
May 06, 2020
Sell 570 USD
Jones Adrian M
Director
- 1000
 0.5702 USD
4 years ago
Mar 24, 2020
Sell 189 USD
Jones Adrian M
Director
- 500
 0.378 USD
4 years ago
May 19, 2020
Sell 1.7 K USD
Jones Adrian M
Director
- 2031
 0.8347 USD
4 years ago
Mar 25, 2020
Sell 557 USD
Jones Adrian M
Director
- 600
 0.9279 USD
4 years ago
Apr 09, 2020
Sell 490 USD
Jones Adrian M
Director
- 1000
 0.49 USD
4 years ago
May 12, 2020
Sell 1.36 K USD
Jones Adrian M
Director
- 2500
 0.546 USD
4 years ago
May 19, 2020
Sell 166 USD
Jones Adrian M
Director
- 200
 0.8314 USD
4 years ago
May 06, 2020
Sell 1.38 K USD
Jones Adrian M
Director
- 2655
 0.52 USD
4 years ago
May 19, 2020
Sell 2.69 K USD
Jones Adrian M
Director
- 3235
 0.8318 USD
4 years ago
May 06, 2020
Sell 521 USD
Jones Adrian M
Director
- 1000
 0.521 USD
4 years ago
May 06, 2020
Sell 526 USD
Jones Adrian M
Director
- 1000
 0.526 USD
4 years ago
May 06, 2020
Sell 264 USD
Jones Adrian M
Director
- 500
 0.528 USD
4 years ago
May 06, 2020
Sell 26.5 USD
Jones Adrian M
Director
- 50
 0.53 USD
4 years ago
May 19, 2020
Sell 1.69 K USD
Jones Adrian M
Director
- 2031
 0.8325 USD
4 years ago
May 06, 2020
Sell 266 USD
Jones Adrian M
Director
- 500
 0.5318 USD
4 years ago
May 06, 2020
Sell 53.2 USD
Jones Adrian M
Director
- 100
 0.5325 USD
4 years ago
May 19, 2020
Sell 1.69 K USD
Jones Adrian M
Director
- 2031
 0.8326 USD
4 years ago
May 06, 2020
Sell 3.38 K USD
Jones Adrian M
Director
- 6256
 0.54 USD
4 years ago
May 06, 2020
Sell 55 USD
Jones Adrian M
Director
- 100
 0.55 USD
4 years ago
May 06, 2020
Sell 517 USD
Jones Adrian M
Director
- 939
 0.5503 USD
3 years ago
Jul 01, 2021
Sell 21.1 K USD
McDonough John
Director
- 18182
 1.16 USD
3 years ago
Jul 01, 2021
Sell 21.1 K USD
CUMMING JOHN W
Director
- 18182
 1.16 USD
3 years ago
Mar 25, 2021
Sell 13.7 K USD
Gibbs Michael Terrence
General Counsel
- 8758
 1.56 USD
3 years ago
Mar 17, 2021
Sell 23.2 K USD
Barclay Alec
Chief Operations Officer
- 12494
 1.86 USD
3 years ago
Mar 17, 2021
Sell 17.7 K USD
Pare Anthony
Chief Commercial Officer
- 9620
 1.84 USD
3 years ago
Feb 23, 2021
Sell 15 K USD
Gibbs Michael Terrence
General Counsel
- 7280
 2.06 USD
3 years ago
Feb 23, 2021
Sell 10.7 K USD
Sprague John M
Chief Financial Officer
- 5250
 2.04 USD
3 years ago
Feb 23, 2021
Sell 15 K USD
Barclay Alec
Chief Operations Officer
- 7280
 2.06 USD
4 years ago
Feb 24, 2020
Sell 3.42 K USD
Sprague John M
Chief Financial Officer
- 4166
 0.82 USD
4 years ago
Feb 24, 2020
Sell 4.76 K USD
Barclay Alec
SVP, Operations
- 5808
 0.82 USD
4 years ago
Feb 24, 2020
Sell 4.76 K USD
Gibbs Michael Terrence
General Counsel
- 5808
 0.82 USD
4 years ago
Feb 24, 2020
Sell 4.76 K USD
Lowery Thomas J.
Chief Scientific Officer
- 5808
 0.82 USD
4 years ago
Feb 11, 2020
Sell 2.46 K USD
Lowery Thomas J.
Chief Scientific Officer
- 3200
 0.77 USD
4 years ago
Feb 11, 2020
Sell 2.46 K USD
Gibbs Michael Terrence
General Counsel
- 3200
 0.77 USD
4 years ago
Feb 03, 2020
Sell 2.89 K USD
Gibbs Michael Terrence
General Counsel
- 3283
 0.88 USD
4 years ago
Feb 03, 2020
Sell 20.9 K USD
McDonough John
Director
- 23754
 0.88 USD
4 years ago
Feb 03, 2020
Sell 6.63 K USD
Lowery Thomas J.
Chief Scientific Officer
- 7535
 0.88 USD
4 years ago
Jan 23, 2020
Sell 66 K USD
McDonough John
Director
- 57417
 1.15 USD
4 years ago
Jan 03, 2020
Sell 6.17 K USD
Elsbree David B
Director
- 5316
 1.16 USD
5 years ago
Sep 11, 2019
Sell 12.3 K USD
Barclay Alec
SVP, Operations
- 4210
 2.92 USD
5 years ago
Jun 11, 2019
Sell 4.63 K USD
Cima Michael J.
Director
- 3240
 1.43 USD
5 years ago
Jun 11, 2019
Sell 13 K USD
Lapidus Stanley
Director
- 9000
 1.44 USD
5 years ago
Jun 11, 2019
Sell 4.89 K USD
CUMMING JOHN W
Director
- 3420
 1.43 USD
5 years ago
Jun 11, 2019
Sell 5.18 K USD
Elsbree David B
Director
- 3600
 1.44 USD
5 years ago
Feb 11, 2019
Sell 10.1 K USD
Lowery Thomas J.
Chief Scientific Officer
- 3005
 3.36 USD
5 years ago
Feb 11, 2019
Sell 10.1 K USD
Gibbs Michael Terrence
General Counsel
- 3005
 3.36 USD
5 years ago
Feb 11, 2019
Sell 27.3 K USD
McDonough John
President & CEO
- 8134
 3.36 USD
5 years ago
Jan 31, 2019
Sell 3.15 K USD
Gibbs Michael Terrence
General Counsel
- 939
 3.35 USD
5 years ago
Feb 01, 2019
Sell 6.32 K USD
Gibbs Michael Terrence
General Counsel
- 1820
 3.47 USD
5 years ago
Jan 31, 2019
Sell 16.4 K USD
McDonough John
President & CEO
- 4895
 3.35 USD
5 years ago
Feb 01, 2019
Sell 32.8 K USD
McDonough John
President & CEO
- 9443
 3.47 USD
5 years ago
Jan 31, 2019
Sell 7.26 K USD
Lowery Thomas J.
Chief Scientific Officer
- 2166
 3.35 USD
5 years ago
Feb 01, 2019
Sell 14.5 K USD
Lowery Thomas J.
Chief Scientific Officer
- 4185
 3.47 USD
6 years ago
Nov 06, 2018
Sell 32 K USD
Lapidus Stanley
Director
- 6048
 5.29 USD
6 years ago
Sep 20, 2018
Sell 298 K USD
Lowery Thomas J.
Chief Scientific Officer
- 48205
 6.18 USD
6 years ago
Sep 18, 2018
Sell 89.9 K USD
Lowery Thomas J.
Chief Scientific Officer
- 14647
 6.14 USD
6 years ago
Sep 18, 2018
Sell 528 K USD
Lowery Thomas J.
Chief Scientific Officer
- 85595
 6.17 USD
6 years ago
Sep 19, 2018
Sell 235 K USD
Lowery Thomas J.
Chief Scientific Officer
- 37902
 6.2 USD
6 years ago
Feb 09, 2018
Sell 26.9 K USD
McDonough John
President & CEO
- 6292
 4.28 USD
6 years ago
Feb 09, 2018
Sell 9.42 K USD
Gibbs Michael Terrence
General Counsel
- 2202
 4.28 USD
6 years ago
Feb 09, 2018
Sell 9.42 K USD
Lowery Thomas J.
Chief Scientific Officer
- 2202
 4.28 USD
6 years ago
Jun 01, 2018
Bought 32.3 K USD
Elsbree David B
Director
+ 4225
 7.65 USD
6 years ago
Jun 05, 2018
Sell 53.2 K USD
Lapidus Stanley
Director
- 6000
 8.87 USD
7 years ago
Nov 16, 2017
Bought 6.17 K USD
Elsbree David B
Director
+ 1500
 4.11 USD
7 years ago
Jun 06, 2017
Bought 3.5 K USD
Dhanda Rahul
SVP of Corporate Development
+ 1000
 3.5 USD
7 years ago
Jun 06, 2017
Bought 17.5 K USD
Spadoro Joanne
Chief Operations Officer
+ 5000
 3.5 USD
7 years ago
Jun 06, 2017
Bought 3.51 K USD
Gibbs Michael Terrence
General Counsel
+ 1000
 3.51 USD
7 years ago
Jun 06, 2017
Bought 35 K USD
Elsbree David B
Director
+ 10000
 3.5 USD
7 years ago
Jun 06, 2017
Bought 14.3 K USD
DEPTULA-HICKS DARLENE M
SVP & Chief Financial Officer
+ 4000
 3.58 USD
7 years ago
May 05, 2017
Bought 5.29 K USD
Cima Michael J.
Director
+ 1400
 3.78 USD
7 years ago
Mar 15, 2017
Bought 59.7 K USD
Elsbree David B
Director
+ 10000
 5.97 USD
7. News
T2 Biosystems, Inc. (TTOO) Q3 2024 Earnings Call Transcript T2 Biosystems, Inc. (NASDAQ:TTOO ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Trip Taylor - Investor Relations John Sperzel - Chairman & Chief Executive Officer John Sprague - Chief Financial Officer Conference Call Participants Yi Chen - H.C. Wainwright Operator Greetings. seekingalpha.com - 2 days ago
T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024 LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the third quarter 2024 and business updates after market close on Thursday, November 14, 2024. globenewswire.com - 1 week ago
T2 Biosystems, Inc. (TTOO) Business Update Conference Call Transcript T2 Biosystems, Inc. (NASDAQ:TTOO ) Business Update Conference Call October 10, 2024 4:30 PM ET Company Participants Trip Taylor - IR John Sperzel - Chairman and CEO Conference Call Participants Eduardo Martinez - H.C. Wainwright Operator Good day, everyone. seekingalpha.com - 1 month ago
T2 Biosystems to Host Business Update Call on October 10, 2024 LEXINGTON, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will host a business update call to provide additional details on recent developments after market close at 4:30pm ET on Thursday October 10, 2024. On the call management also plans to address select questions from shareholders that can be submitted in advance to the investor relations team at ir@T2Biosystems.com . globenewswire.com - 1 month ago
T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens LEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has entered into a multi-year exclusive U.S. agreement with Cardinal Health (NYSE: CAH),. Under the agreement, Cardinal Health will have exclusive rights to sell T2 Biosystems' FDA-cleared direct-from-blood diagnostics for the rapid detection of sepsis-causing pathogens, including the T2Dx® Instrument, the T2Bacteria® Panel, and the T2Candida® Panel. globenewswire.com - 1 month ago
T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union LEXINGTON, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has successfully defended against an opposition filed against a key patent for its direct-from-whole blood detection method in the European Union. globenewswire.com - 1 month ago
T2 Biosystems to Participate in the H.C. Wainwright 26th Annual Global Investment Conference LEXINGTON, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming H.C. Wainwright 26th Annual Global Investment Conference. globenewswire.com - 2 months ago
T2 Biosystems to Attend Upcoming Investor Conferences LEXINGTON, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in two upcoming investor conferences in August 2024: globenewswire.com - 3 months ago
T2 Biosystems, Inc. (TTOO) Q2 2024 Earnings Call Transcript T2 Biosystems, Inc. (NASDAQ:TTOO ) Q2 2024 Earnings Conference Call July 29, 2024 4:30 PM ET Company Participants Trip Taylor - Investor Relations John Sperzel - Chairman & Chief Executive Officer John Sprague - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Operator Greetings, and welcome to T2 Biosystems, Inc. Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 3 months ago
T2 Biosystems Announces Commercial Expansion Through Malaysia and Indonesia Distributor LEXINGTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of a territory exclusive distribution agreement in Malaysia and Indonesia. Under the terms of the agreement, T2 Biosystems will sell the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance® Panel through the newly appointed distributor. globenewswire.com - 3 months ago
T2 Biosystems to Report Second Quarter 2024 Financial Results and Business Updates on July 29, 2024 LEXINGTON, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the second quarter 2024 and business updates after market close on Monday, July 29, 2024. globenewswire.com - 3 months ago
T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements LEXINGTON, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) on May 21, 2024 informing the Company that it has regained compliance with the market value of listed securities (“MVLS”) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the “Rule”) for continued listing on the Nasdaq Capital Market. globenewswire.com - 5 months ago
8. Profile Summary

T2 Biosystems, Inc. TTOO

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 8.69 M
Dividend Yield 0.00%
Description T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Contact 101 Hartwell Avenue, Lexington, MA, 02421 https://www.t2biosystems.com
IPO Date Aug. 7, 2014
Employees 113
Officers Mr. Michael Terrence Gibbs Esq. Senior Vice President, General Counsel & Company Secretary Dr. Roger Smith Ph.D. Senior Vice President of Science Research & Development Mr. John J. Sperzel III, B.Sc. President, Chief Executive Officer & Chairman Mr. John M. Sprague CPA Chief Financial Officer Ms. Kelley J. Morgan Chief People Officer Mr. Brett A. Giffin Chief Commercial Officer